Clinical

Dataset Information

0

Phase II Clinical Study Evaluating the Efficacy and Safety of Cetuximab Rechallenge in Patients with Wild-Type RAS, Unresectable, Progressive/Recurrent Colorectal Cancer Refractory to Fluoropyrimidines, Oxaliplatin, Irinotecan, Cetuximab and Bevacizumab: The E-Rechallenge Trial

ABSTRACT: Interventions: administration of Cetuximab Primary outcome(s): Response rate (RR) Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2631760 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Skin Toxicity as Predictor of Survival in Refractory Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy.
| S-EPMC8616320 | biostudies-literature
Unknown Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
| S-EPMC8531995 | biostudies-literature
Unknown CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated <i>RAS</i>/<i>BRAF</i> Wild-Type mCRC Patients.
| S-EPMC9272566 | biostudies-literature
Unknown Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
| S-EPMC6439839 | biostudies-literature
Unknown Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study.
| S-EPMC11343749 | biostudies-literature
Unknown Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
| S-EPMC10196928 | biostudies-literature
Clinical Phase II crinical trial of cetuximab rechallenge with KRAS wild-type unresectable/recurrent colorectal cancer
| 2625092 | ecrin-mdr-crc
Unknown FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
| S-EPMC5348362 | biostudies-literature
Unknown Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial.
| S-EPMC11004834 | biostudies-literature
Unknown Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
| S-EPMC10507485 | biostudies-literature